Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roivant Sciences Ltd
(NQ:
ROIV
)
11.92
+0.01 (+0.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roivant Sciences Ltd
< Previous
1
2
3
4
5
6
7
8
Next >
Vivek 'Da Vek' Ramaswamy: The 2024 Presidential Candidate Who Might Just Rap His Inauguration Speech
July 28, 2023
Donald Trump and Ron DeSantis have been the runaway favorites for the GOP nomination in the 2024 election, but there’s one candidate that has been climbing up the polls and gaining support from...
Via
Benzinga
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
July 27, 2023
From
Roivant Sciences
Via
GlobeNewswire
3 Biotech Stocks for Getting Rich in 2023
July 18, 2023
These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist.
Via
InvestorPlace
2 Nasdaq Stocks That Could Soar This Week
July 16, 2023
BridgeBio Pharma and Roivant Sciences could make big moves this week.
Via
The Motley Fool
Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories
July 14, 2023
Benzinga
Via
Benzinga
Roivant Sciences's Return on Invested Capital Insights
June 29, 2023
Via
Benzinga
Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover
July 14, 2023
The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed.
Via
Investor's Business Daily
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
July 14, 2023
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)
Via
Benzinga
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
July 11, 2023
Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others
From
Roivant Sciences
Via
GlobeNewswire
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
June 29, 2023
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market...
Via
Benzinga
Analyst Expectations for Roivant Sciences's Future
June 29, 2023
Via
Benzinga
Why Shares of Roivant Sciences Rose Wednesday
June 28, 2023
The pharmaceutical company released fourth-quarter earnings.
Via
The Motley Fool
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
June 28, 2023
From
Roivant Sciences
Via
GlobeNewswire
Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness'
June 28, 2023
Via
Benzinga
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
June 28, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Roivant Sciences Stock is Trading Higher Today
June 22, 2023
Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with
Via
Benzinga
A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout
June 22, 2023
The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis.
Via
Investor's Business Daily
5 Analysts Have This to Say About Roivant Sciences
June 08, 2023
Via
Benzinga
Why Shares of Roivant Sciences Jumped This Week
April 20, 2023
The company's stock benefited from another company's buyout.
Via
The Motley Fool
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
June 26, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 22, 2023
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private...
Via
Benzinga
Why Roivant Sciences Stock Is Perking Up Today
June 22, 2023
Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock.
Via
The Motley Fool
Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday
June 22, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
June 22, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
June 21, 2023
From
Roivant Sciences
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
June 08, 2023
Via
Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission
May 16, 2023
Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old...
Via
Benzinga
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
May 16, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
April 23, 2023
Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.